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Abstract. The use of anti-chlamydial antibiotics for trachoma control is based on the assumption that most people
with clinically active disease have conjunctival infection with Chlamydia trachomatis. In high prevalence areas, this is
generally true. As prevalence decreases, however, the positive predictive value of clinical signs for C. trachomatis
infection also decrease. In this paper, the case for using laboratory assays to guide trachoma control strategies is
presented, molecular methods for diagnosis (such as a ligase chain reaction and a polymerase chain reaction [PCR]) are
compared with earlier techniques, and recent findings of ongoing studies using a quantitative PCR are reviewed. In
addition, the contribution of genotyping to our understanding of the epidemiology and biology of C. trachomatis is
considered.
INTRODUCTION
Trachoma is caused by ocular infection with the intracellu-
lar bacterium Chlamydia trachomatis,1 and antibiotics have
played a key role in trachoma control efforts since the late
1930s.2 However, sulfonamides proved to be too toxic to be
used in mass treatment campaigns,3 and tetracycline cannot
be given systemically to children. The impact of topical tet-
racycline was limited, presumably (at least in part) because
compliance was poor with the prolonged courses needed to
cure infection.4 The demonstration that a single oral dose of
azithromycin is as effective in the treatment of active tra-
choma as a six-week course of tetracycline ointment5−8 was a
major advance. When given to whole communities, azithro-
mycin produces a greater reduction in the prevalence of con-
junctival C. trachomatis infection than does topical tetracy-
cline.9 This has encouraged the World Health Organization
(WHO) to set 2020 as the target date for elimination of tra-
choma as a public health problem.10
The surgery, antibiotics, facial cleanliness, and environ-
mental improvement (SAFE) strategy for the elimination of
blinding trachoma relies heavily on the use of mass treatment
of endemic communities with antibiotics. The evidence base
for the antibiotics component is stronger than that for the
other aspects of SAFE.4,11 However, azithromycin is an ex-
pensive drug, and although it is being generously donated by
its manufacturers to control programs in 10 countries, it is
important that it is targeted to the communities, and the
population groups within those communities, where it will
have maximum impact.
WHY IS A LABORATORY TEST NEEDED FOR
TRACHOMA CONTROL?
The WHO recommends that whole communities should be
treated with antibiotics when the prevalence of follicular ac-
tive trachoma (TF) exceeds 20% in children 1−10 years old.12
The prevalence of active trachoma is determined by clinical
examination of the everted upper eyelid of a sample of chil-
dren, and TF is defined according to the WHO simplified
system (Table 1).13In communities with a prevalence of TF in
children less than 20%, selective mass treatment is recom-
mended, but there is no consensus as to who should be
treated. Various strategies have been proposed, including the
treatment of all children with active disease and their house-
hold contacts, the treatment of all children less than 10 years
of age, and the treatment of all women and children. The
relative impact of these different strategies has not been de-
termined. The only comparison performed to date evaluated
(in a low prevalence area) mass treatment of 1−10-year-old
children against treatment of children with active disease plus
members of their households; no significant differences in
outcome were found.14 Furthermore, it is not clear what the
time interval between treatments should be, nor how many
rounds of treatment should be given.
The purpose of antibiotic treatment is to cure ocular C.
trachomatis infection. Community-based mass treatment is
given in the hope that this will reduce the reservoir of infec-
tion in the community, leading to reduced or interrupted
transmission. Unfortunately, the presence or absence of TF,
defined according to WHO criteria, does not correlate per-
fectly with the presence of ocular C. trachomatis infection, for
the following reasons: 1) C. trachomatis is not the only cause
of follicular conjunctivitis; 2) there is a delay between the
establishment of infection and the appearance of the charac-
teristic signs of active trachoma in humans and in primate
models;15−17 and 3) the subconjunctival follicles on which the
clinical diagnosis is based can persist for weeks or months
after the infection has resolved.15−19 Laboratory tests for the
identification of individuals with ocular C. trachomatis infec-
tion can 1) help target antibiotic treatment to groups in whom
it will have most impact; 2) be used to measure the impact of
antibiotic treatment and of interventions to reduce transmis-
sion; 3) help to determine the optimal frequency of commu-
nity-based treatment; and 4) be useful in identifying commu-
nities in which transmission has been interrupted, or reduced
to such a level that control efforts are no longer required.
Laboratory tests that allow the infecting serotype or strain to
be identified can shed additional light on the way in which
infection is transmitted, and on sources of reinfection after
community-based treatment.
WHICH LABORATORY TEST IS MOST USEFUL?
In the 1960s, large epidemiologic studies of trachoma were
conducted in The Gambia, Saudi Arabia, Taiwan, and Ethio-
pia in preparation for vaccine trials. Infected individuals were
identified by staining conjunctival smears for chlamydial in-
clusions or by culture in fertile hen eggs. The staining method
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lacked sensitivity, and culture was laborious, expensive, and
required a cold chain for the transport of specimens. Sub-
sequent studies in Iran used the presence of antibodies to
C. trachomatis in tears detected by the micro-immuno-
fluorescence test of Wang and Grayston20 as a proxy for in-
fection.21 This method could also be used to identify the in-
fecting serotype, and helped to define the importance of
transmission within the household unit.
In the 1980s, antigen detection methods (direct fluores-
cence or enzyme immunoassay) were used to identify C. tra-
chomatis-infected individuals in Tanzania and The Gam-
bia.22,23 The sensitivities of these tests were similar to culture,
but they were simpler to perform, and did not require that
specimens be kept cold. It was suggested that the presence of
chlamydial antigen in samples that were negative by culture
implied that persistent, non-replicating C. trachomatis may be
present in some individuals, and contribute to the pathogen-
esis of blinding trachoma,24 but it is possible that this phe-
nomenon merely reflected the difficulty inherent in culturing
C. trachomatis from samples collected in the field.
MOLECULAR TOOLS
Molecular methods, in particular nucleic acid amplification
tests (NAATs), for the detection, quantification, and geno-
typing of ocular C. trachomatis infection have furthered our
understanding of the epidemiology of trachoma in the past
decade. New insights provided by NAATs can be used to
refine our strategies for the control of blinding trachoma, as
described below.
NAATs to diagnose infection. NAATs are significantly
more sensitive than other methods of diagnosing C. tra-
chomatis infection.25 The application of these tests in the di-
agnosis of ocular C. trachomatis infection in trachoma-
endemic communities has led to some surprising findings. For
example, in Nepal, very few infected individuals were identi-
fied in communities with clear clinical evidence of blinding
trachoma, whereas in Tanzania, The Gambia, and Egypt, a
high prevalence of infection was found in individuals living in
endemic communities, even for subsets without clinical evi-
dence of active disease. In-house polymerase chain reaction
(PCR) assays were first used to diagnose ocular infection in
trachoma-endemic communities in Tanzania and The Gam-
bia.16,26
In Tanzania, a PCR assay targeting the outer membrane
protein A (ompA) gene detected C. trachomatis in a higher
proportion of subjects with active trachoma than did the di-
rect fluorescent antibody (DFA) assay (Syva Microtrak™;
Syva, Palo Alto, CA). Fifty-four percent of those with only
follicular trachoma (TF) were positive by the PCR (compared
with 28% by the DFA), as were 95% of those with intense
trachoma (TI) (compared with 60% by the DFA). However,
a surprisingly high proportion of subjects without clinical evi-
dence of active trachoma according to WHO criteria were
positive by the PCR (24% compared with 1% by the DFA).26
In The Gambia, a PCR assay targeting the cryptic chlamyd-
ial plasmid detected C. trachomatis-specific DNA in 144
(72%) of 200 individuals with active trachoma and in 85
(7.5%) of 1,132 without active trachoma, according to the
WHO criteria. Conjunctival follicles were present in 31 (36%)
of 85 of these individuals, and corneal vascularization (pan-
nus), typical of trachoma, was present in 11 (13%). The PCR-
positive subjects without active trachoma by WHO criteria at
baseline were significantly more likely to have developed ac-
tive trachoma according to these criteria one and six months
later than were PCR-negative subjects.16
Several NAATs are commercially available for the diagno-
sis of C. trachomatis infection. These were developed for the
diagnosis of genital infection, and only two, the Amplicor™
PCR assay developed by Roche Diagnostic Systems (Pleas-
anton, CA), and the LCx™ ligase chain reaction (LCR) de-
veloped by Abbott Laboratories (Abbott Park, IL), have
been used to diagnose ocular infection in trachoma.
In the Surkhet District of Nepal, 726 children 1−10 years
old were examined in six villages.19 Forty-six (6%) were
found to have clinical evidence of trachoma, according to the
simplified WHO criteria.13 Swabs were taken from these 46
children and from 44 controls without clinical trachoma. They
were stored at 4°C, transported to San Francisco, California,
and tested by the LCR. None of the 90 swabs were positive.
Twelve samples from clinically active children were retested,
after dilution, to rule out the presence of inhibitors, and re-
tested again with a separate LCR that targeted a different C.
trachomatis gene. All were consistently negative.19
In the Kailali District of Nepal, eye swabs were taken (by
the same group of investigators) from 24 children with clini-
cally active trachoma in four villages in which the prevalence
of active disease was < 10% in children 1−10 years old. C.
trachomatis was detected by the LCR in only 2 (8%) of 24. In
contrast, in another village in Kailali in which the prevalence
of active trachoma was 39% in children 1−10 years old, C.
trachomatis was detected by the LCR in 15 (63%) of the 24
children with active disease from whom swabs were taken.18
As part of the same study, in Dongfang District of Hainan
Province in China, eye swabs were taken from 25 individuals
with active trachoma. The overall prevalence of active disease
in children 1−7 years old was 2% in the district, although
there was a relatively high prevalence of trachomatous scar-
ring and of trichiasis among adults (15% and 3%, respec-
tively), suggesting that trachoma had been a more serious
problem in the recent past. C. trachomatis was detected by the
LCR in 2 (8%) of 25 subjects.18
These results suggest that in communities where the preva-
lence of active trachoma (determined clinically) is < 10%, the
prevalence of ocular C. trachomatis infection is extremely
low. It seems unlikely that sustained transmission of infec-
tion occurs in such communities, suggesting that antibiotic
TABLE 1
The World Health Organization simplified clinical grading system
for trachoma13
TF: Trachomatous inflammation—follicular: the presence of five
or more follicles at least 0.5 mm in diameter, in the central part
of the upper tarsal conjunctiva
TI: Trachomatous inflammation—intense: pronounced
inflammatory thickening of the upper tarsal conjunctiva
obscuring more than half the normal deep tarsal vessels
TS: Trachomatous conjunctival scarring: the presence of easily
visible scars in the tarsal conjunctiva
TT: Trachomatous trichiasis: at least one eyelash rubs on the
eyeball, or evidence of recent removal of in-turned eyelashes
CO: Corneal opacity: easily visible corneal opacity over the pupil,
so dense that at least part of the pupil margin is blurred when
viewed through the opacity
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treatment is unnecessary there for the control of blinding
trachoma.
The LCR was used by Schachter and others to detect ocular
C. trachomatis infection in endemic communities in The
Gambia, Tanzania, and Egypt.9 Trachoma was highly en-
demic in all communities, with the prevalence of active dis-
ease, according to the WHO simplified criteria,13 ranging
from 30% in The Gambia to 64% in Tanzania, among chil-
dren 1−10 years old. Among individuals with mild active tra-
choma (TF), C. trachomatis was detected in 41% in Tanzania,
52% in The Gambia, and 61% in Egypt. The corresponding
prevalences of C. trachomatis infection in children with severe
active disease (TI) were 55%, 70%, and 81%, respectively.
Surprisingly, the prevalence of C. trachomatis infection was
also high among subjects without clinically active disease in
The Gambia (462 of 1,470, 31%) and Egypt (466 of 1,661,
28%). Of concern for trachoma control programs, the preva-
lence of infection was high among adults, who are not nor-
mally considered a significant reservoir of infection, in both
countries (> 20% in Egypt, and > 30% in The Gambia among
subjects > 10 years old). In Tanzania, the prevalence of in-
fection among those without active disease was considerably
lower in this study (83 of 1,809, 4.6%)9 than in the previous
Tanzanian study of Bobo and others,26in which it was 24%.
Less than 10% of those > 10 years old were infected in the
later study.
What significance do these findings have for control pro-
grams? Initially, they suggest that adults are as important a
reservoir of infection as children. Moreover, the prevalence of
infection was similar in men and women at all three sites,
suggesting that targeting women and children alone may not
be an effective control strategy. Conversely, the fact that most
subjects without active disease show negative results for C.
trachomatis in less sensitive (non-NAAT) tests suggest that
they harbor low numbers of organisms. Does this represent
productive infection with replicating organisms that could be
transmitted to others, or merely contamination with dead or-
ganisms or chlamydial DNA?
Quantitative PCR. This question could be addressed in
various ways. The number of organisms or the amount of C.
trachomatis DNA in ocular samples from those with and with-
out clinical signs could be measured using real-time quanti-
tative DNA amplification methods; markers of replication
and viability could be measured, e.g., isolation in tissue cul-
ture or by mRNA expression; longitudinal studies could
document the presence and amount of C. trachomatis shed-
ding and corresponding clinical signs; and household contacts
of these subjects could be followed up to determine which
subjects are most likely to infect their household contacts.
The first report of a semi-quantitative PCR method to de-
termine the amount of chlamydial DNA in eye swabs in a
trachoma endemic population described a longitudinal study
conducted in Kongwa District, Tanzania.27 Fifty-three chil-
dren from 33 families were examined every week for three
months. Children with active disease had significantly higher
chlamydial loads than those with no signs. Those with persis-
tent infection had higher chlamydial loads than those with
sporadic infections, and were more likely to have intense in-
flammatory trachoma (TI).13
A quantitative PCR (Q-PCR) directed at the ompA gene
has now been developed using the LightCycler (Roche Mo-
lecular Systems, Branchburg, NJ).28,29 The target is a 123-
basepair sequence of ompA constant domain 3, which is
known to be highly conserved among C. trachomatis strains.
OmpA is found in a single copy on the chlamydial chromo-
some. The LightCycler uses a true kinetic (real-time) quan-
titative PCR format. Reactions take place in closed glass cap-
illaries. The high surface-to-volume ratio of capillaries mini-
mizes the cost of reagents and allows rapid heat transfer and
therefore rapid thermal cycling.30 Because capillaries are op-
tically clear, analysis of product generation can occur through
detection and quantification of a fluorescent reporter (SYBR
Green I; Molecular Probes, Eugene, OR) after each exten-
sion step.30,31 Unfortunately, a small sample volume also has
a disadvantage: it increases the effect of sampling variability,
particularly for low-copy number positive samples. This
means that the sensitivity of the test is lower than commercial
qualitative PCRs, despite the fact that the LightCycler assay
is optimized to reproducibly amplify one copy of the target
sequence if present in a capillary. To compensate for this
disadvantage, swabs can first be screened using a qualitative
PCR or LCR, such as the Amplicor PCR, which is known to
be highly sensitive.25 Positive specimens are then quantified
in the LightCycler. In addition, quantifying two separate ali-
quots of each positive specimen should reduce random error
due to sampling variation.
Quantitative PCR has recently been used to determine the
distribution of ocular C. trachomatis infection in three Afri-
can trachoma-endemic communities chosen to be representa-
tive of populations with differing levels of disease endemic-
ity.29 Two of these communities were in Tanzania (Rombo
and Kongwa Districts), and one in The Gambia (Jareng Dis-
trict). Samples were taken from each consenting individual at
baseline using a dry sterile Dacron swab applied in a highly
standardized fashion to the everted upper tarsal conjunctiva.
A plot of the number of copies of ompA determined per swab
versus the age of the individual is shown for each site in
Figure 1. Chlamydial loads are shown on the vertical axis
against a log scale; uninfected individuals (load  0) are
therefore not represented on the plot. There was a strong
tendency for higher loads to be found in younger children in
Kongwa and Rombo, the two communities with higher preva-
lences of disease. High loads were more diffusely distributed
by age in Jareng, which had the lowest prevalence of disease.
One possible explanation for this association is that the pro-
pensity to develop protective immunity to ocular C. tra-
chomatis infection is dependent on the level of endemicity.
Ninety percent of the total community ocular load of C. tra-
chomatis was found in children 0−6.5 years old in Kongwa, in
children 0−6.6 years old in Rombo, and in individuals 0−27.5
years old in Jareng.29
There were no significant differences in either the preva-
lence or load of infection between males and females at any of
the three sites. This was consistent with the findings for preva-
lence of infection by the LCR in the study of Schachter and
others,9 but is somewhat at odds with current treatment pro-
tocols in low prevalence areas, which often recommend anti-
biotics for adult women but not adult men.
The relationship between infection and disease is also of
interest. Loads were highest in those with severe inflamma-
tory trachoma (TI), but a surprisingly high proportion of in-
dividuals with trachomatous conjunctival scarring (TS), with-
out evidence of active disease, had low-copy number infec-
tions.29 The latter finding is important because there is some
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evidence that women with TS are more likely to develop
trichiasis if they test positive for ocular C. trachomatis.32
However, given the low copy numbers, it seems unlikely that
these older individuals with TS alone are an important reser-
voir of infection.
In contrast to those with high copy numbers, C. trachomatis
was isolated in tissue culture from only a small proportion of
those with low ompA loads. This might mean that few of these
individuals are infected with live, replicating organisms, or
that there is a stage in the natural history of ocular chlamydial
FIGURE 1. Individual ocular chlamydial loads versus age in three trachoma-endemic communities, measured as the quantitative polymerase
chain reaction−determined number of copies of the outer membrane protein A (ompA) gene per standard conjunctival swab. Only data for
individuals with positive swabs are displayed. Prevalences of active disease in study subjects were A, 312 (36%) of 871 in Kongwa, central
Tanzania; B, 174 (18%) of 956 in Rombo, northern Tanzania; and C, 103 (8%) of 1,319 in Jareng, The Gambia.
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infection during which non-culture test results are positive but
viable organism cannot be isolated.24 Follow-up studies are in
progress to determine whether this group of individuals rep-
resents a source of infection for their household contacts.
Following baseline swabbing, mass distribution of single-
dose azithromycin was undertaken in all three communities,
and at 2, 6, 12, and 18 months, swabs were obtained from all
consenting residents for determination of ocular chlamydial
load. At the time this review was prepared, complete post-
treatment Q-PCR data were available from only one site. At
that site (Kahe Mpya, Rombo District in northern Tanzania),
nearly 94% of 978 resident individuals took azithromycin at
baseline, and an additional 4% were given two tubes of 1%
tetracycline eye ointment because according to Tanzanian
guidelines they were ineligible to receive azithromycin. An
adjusted geometric mean of the total load of ocular C. tra-
chomatis in the community was reduced to 14% of its baseline
level two months after mass treatment, 8% at six months, and
5% at 12 months.33 In summary, this study used Q-PCR to
provide evidence of the dramatic and sustained effect of
single-dose azithromycin on the prevalence and intensity of
ocular chlamydial infection.
The Q-PCR provides useful information on which to base
antibiotic treatment strategies by identifying the groups with
the highest infectious load: these groups need to be targeted
for treatment. The optimal treatment strategy may differ in
communities with different levels of endemicity.
Molecular strain typing (genotyping). Small studies con-
ducted in Taiwan and Iran in the 1970s and 1980s, which used
the micro-immunofluorescence test to type ocular isolates or
tear antibody, showed that a single serovar of C. trachomatis
usually accounts for all infections in any given household,
confirming the importance of transmission within the fam-
ily.34,35 Molecular genotyping, usually performed by sequenc-
ing the ompA gene after its amplification by a PCR, has en-
abled us to conduct much larger studies. These investigations
have generally confirmed that a single household contains a
single genotype, that more than one genotype is present in
most if not all trachoma-endemic communities, and that
single nucleotide polymorphisms are commonly found in ocu-
lar strains.
The ompA gene codes for the chlamydial major outer
membrane protein (MOMP) that contains the serovar-
specific epitopes of C. trachomatis. It is a strong candidate for
a chlamydial vaccine since MOMP-specific monocolonal an-
tibodies neutralize infection in vitro.36 There is evidence from
non-human primate models that resistance to ocular C. tra-
chomatis is serovar specific.37 It was therefore interesting to
see whether it is possible for a single ompA genotype to per-
sist in a trachoma endemic community, or whether persis-
tence in the community requires the appearance of mutations
in ompA to escape immunologic pressure. A longitudinal
study in two Gambian villages identified four variant strains
of C. trachomatis serovar A and four of serovar B. Each vari-
ant differed from the prototype strain by a single nucleotide.
Two genovar A and two genovar B variants comprised 87%
of the strains. Although there was some flux in the prevalence
of individual strains over time, their overall distribution re-
mained remarkably stable over a 22-month period. There was
no evidence of major antigenic shift resulting from recombi-
nation at ompA locus.38,39 This is in one sense encouraging,
since it seems that C. trachomatis is not prone to rapid mu-
tation in the ompA gene that might compromise vaccine effi-
cacy, but conversely it implies that a given strain of C. tra-
chomatis can persist for long periods in individuals and com-
munities in spite of the presence of an immune response to
that genotype.
Although community-based antibiotic treatment can dra-
matically reduce the prevalence of ocular chlamydial infec-
tion for 18 months or more if a high enough coverage is
achieved,33 it is often followed by rapid re-emergence of in-
fection when coverage is low or moderate. In designing the
optimal regimen for antibiotic treatment, it is important to
know if re-emergent infection represents treatment failure,
reinfection from untreated members of the community, or
reinfection from sources outside the community. In theory,
strain typing may enable us to distinguish between these pos-
sibilities; but in practice, since most households contain only
one strain, it has been difficult to distinguish treatment failure
from reinfection at the household level.38,40,41
In addition to furthering our understanding of the epide-
miology of infection and impact of treatment, molecular ap-
proaches are of fundamental importance to basic science re-
search, which may ultimately lead to the development of the
long-awaited vaccine against trachoma. For example, C. tra-
chomatis strains isolated from eyes in trachoma-endemic
communities are almost invariably of serovar A, B, Ba, or C,
whereas genital isolates are almost always of serovars D-K.
The biologic differences underlying this distinct tropism were
unknown until recently, when it was shown that a wide range
of ocular strains all contained a mutation in the tryptophan
synthase (trpBA) gene that rendered it non-functional;
whereas all genital strains contained a functioning trpBA
gene.42 This observation is likely to be of fundamental im-
portance to our understanding of host-pathogen relation-
ships.
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